Changes in antigen expression on differentiating HL60 cells treated with dimethylsulphoxide, all-trans retinoic acid, alpha1,25-dihydroxyvitamin D3 or 12-O-tetradecanoyl phorbol-13-acetate.

Abstract:

:We describe changes in antigen expression on HL60 cells with differentiation into granulocytes induced by all-trans retinoic acid (ATRA) or dimethylsulphoxide (DMSO), into monocytes by alpha1,25-dihydroxyvitamin D3 (D3), or into macrophages by 12-O-tetradecanoyl phorbol-13-acetate (TPA). Undifferentiated cells expressed CD13, CD14 (at a low level), CD15, CDw17, CD32, CD33, CD49e, CD63, CD64, CDw65, CD71 and CD87 antigens and bound the unclustered mAb D171 and Mo5. Differentiated and undifferentiated cells were negative for CD16, CD34, CD61, CD66abcde, CD68, CD88, CDw90 and CD93. Four panels of markers were identified whose expression changes significantly following differentiation. CD15, CD49e, CD63, CDw65, CD71 and mAb D171 and IGR-2,1A6 for DMSO; CD13, CD15, CDw17, CD49e, CD63, CDw65, CD71, CD87, CDw92 and mAb D171 and IGR-2,1A6 for ATRA; CD14, CD31, CD35, CD71, CD87, CDw92 and mAb D171 and BRIC18 for D3; CDw12, CD13, CD15, CD31, CD35, CD49e, CD71, CD87, CDw92 and mAb D171 for TPA. These will be useful for analyzing the pathways that regulate differentiation, whether the observed changes are consequences of differentiation or more direct effects of the inducers. HL60 cells provide a model for investigating the regulation of these antigens.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Trayner ID,Bustorff T,Etches AE,Mufti GJ,Foss Y,Farzaneh F

doi

10.1016/s0145-2126(98)00041-1

subject

Has Abstract

pub_date

1998-06-01 00:00:00

pages

537-47

issue

6

eissn

0145-2126

issn

1873-5835

pii

S0145212698000411

journal_volume

22

pub_type

杂志文章
  • Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years.

    abstract::Prospective data are needed to ascertain the impact of iron chelation therapy in patients with myelodysplastic syndromes. The present 5-year prospective registry analysis was conducted to compare clinical outcomes between chelated and nonchelated patients with lower-risk myelodysplastic syndromes and transfusional iro...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2017.01.033

    authors: Lyons RM,Marek BJ,Paley C,Esposito J,McNamara K,Richards PD,DiBella N,Garcia-Manero G

    更新日期:2017-05-01 00:00:00

  • The morphological subcategories of acute monocytic leukemia (M5a and M5b) share similar immunophenotypic and cytogenetic features and clinical outcomes.

    abstract::Acute monocytic leukemia (M5) is a subtype of acute myeloid leukemia (AML) with two distinct morphologic subcategories, M5a and M5b. We compared the immunophenotype, cytogenetics and clinical outcome of AML M5 with non-M5 AML and also compared M5a with M5b. One hundred and twelve M5 (76 M5a, 36 M5b) and 726 non-M5 cas...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2007.06.019

    authors: Villeneuve P,Kim DT,Xu W,Brandwein J,Chang H

    更新日期:2008-02-01 00:00:00

  • Is cigarette smoking a risk factor for non-Hodgkin's lymphoma or multiple myeloma? Results from the Lutheran Brotherhood Cohort Study.

    abstract::Among 17,633 U.S. white male insurance policy holders whose use of tobacco was characterized in a 1966 self-administered questionnaire, there were 49 deaths from non-Hodgkin's lymphoma (NHL) and 21 from multiple myeloma (MM) during a 20-year follow-up. Men who had ever smoked cigarettes had an elevated mortality from ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(92)90011-u

    authors: Linet MS,McLaughlin JK,Hsing AW,Wacholder S,Co Chien HT,Schuman LM,Bjelke E,Blot WJ

    更新日期:1992-06-01 00:00:00

  • Simultaneous development of humoral and cellular tumor-specific immunity against L1210 mouse leukemia.

    abstract::We have recently described that a variant of L1210 leukemia cell (L1210/LN-1) originally fused with Lesch-Nyhan fibroblast is highly immunogenic for inducing tumor-specific transplantation immunity in (BALB/cxDBA/2)F1 mice. This finding has clearly been confirmed in the present study by in-vitro cell-mediated cytotoxi...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(85)90316-9

    authors: Kawashima K,Isobe K,Nagase F,Yokochi T,Nagura E,Hasegawa Y,Morishita H,Yamada K,Nakashima I

    更新日期:1985-01-01 00:00:00

  • Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.

    abstract::Peripheral neuropathy (PN), with neuropathic pain as main symptom, represents the dose-limiting toxicity of the proteasome inhibitor bortezomib. Aim of this study was to compare the incidence, risk factors, severity and outcome of PN and neuropathic pain in patient treated with bortezomib up-front or at relapse. We st...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.07.022

    authors: Corso A,Mangiacavalli S,Varettoni M,Pascutto C,Zappasodi P,Lazzarino M

    更新日期:2010-04-01 00:00:00

  • Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?

    abstract:BACKGROUND:Analyses suggest MDS patients with higher serum ferritin levels (SF) have inferior overall survival (OS), in one study across MDS subtypes. Multiple analyses suggest those with high SF receiving iron chelation therapy (ICT) have superior OS, but which MDS subtypes benefit from ICT remains undefined. METHODS...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2017.11.005

    authors: Wong SA,Leitch HA

    更新日期:2018-01-01 00:00:00

  • Monoclonal antibodies raised against K562 cells reacted with human haematopoietic pluripotent stem cells.

    abstract::We describe the properties of three monoclonal antibodies (McAbs) (21H73, 37G7 and 49C12) against K562 cell surface antigens correlated with differentiation induced by 12-O-tetradecanoyl phorbol-13-acetate (TPA). Each of the McAbs immunoprecipitated K562 cell surface antigen with molecular weight (MW) of approximately...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(91)90121-9

    authors: Kubota Y,Tanaka T,Irino S

    更新日期:1991-01-01 00:00:00

  • Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy.

    abstract::We investigated protracted low-dose oral Clofarabine for the treatment of myelodysplastic syndromes (MDS). Adults with an International Prognostic Scoring System (IPSS) score of INT-1 or higher who had failed first line therapy were eligible. INT-1 patients had to be transfusion-dependent. We started with oral Clofara...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2015.05.004

    authors: Rudrapatna VK,Morley K,Boucher KM,Pierson AS,Shull CT,Kushner JP,Shami PJ

    更新日期:2015-08-01 00:00:00

  • Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan.

    abstract::Atypical chronic myeloid leukemia (aCML) and chronic neutrophilic leukemia (CNL) are rare BCR-ABL1 fusion gene-negative myeloid neoplasms with a predominance of neutrophils. Since no standard therapeutic strategy currently exists for these diseases, we retrospectively evaluated the outcomes of allogeneic hematopoietic...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2018.11.003

    authors: Itonaga H,Ota S,Ikeda T,Taji H,Amano I,Hasegawa Y,Ichinohe T,Fukuda T,Atsuta Y,Tanizawa A,Kondo T,Miyazaki Y

    更新日期:2018-12-01 00:00:00

  • Stimulation of haemopoietic stem cell proliferation: characteristics of the stimulator-producing cells.

    abstract::Media conditioned by regenerating murine bone marrow cells contain a stimulator of haemopoietic stem cell proliferation. Fractionated cell populations have been examined for production of this stimulatory activity in order to characterize its cellular source. The stimulator is produced by adherent, phagocytic, radiore...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(82)90010-8

    authors: Wright EG,Ali AM,Riches AC,Lord BI

    更新日期:1982-01-01 00:00:00

  • Treatment of pediatric myelodysplastic syndromes and juvenile myelomonocytic leukemia: the Brazilian experience in the past decade.

    abstract:BACKGROUND:Therapy strategies for myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukemia (JMML) vary considerably. OBJECTIVE:To review the treatment of Brazilian children who were diagnosed with MDS or JMML in the past decade and reported to the Brazilian Cooperative Group on Pediatric Myelodysplastic Sy...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2004.01.008

    authors: Valera ET,Latorre Mdo R,Mendes WL,Seber A,Lee ML,de Paula MJ,Loggetto SR,Velloso E,Niero-Melo L,Lopes LF,Brazilian Cooperative Group on Pediatric Myelodysplastic Syndromes.

    更新日期:2004-09-01 00:00:00

  • THP-1 monocytic leukemia cells express Fas ligand constitutively and kill Fas-positive Jurkat cells.

    abstract::Normal human monocytes express Fas and are susceptible to Fas ligand (FasL)-induced apoptosis. Because the myeloid leukemia cell lines HL-60 and THP-1 can be differentiated into functional monocytes and macrophages, we studied their expression of Fas and Fas ligand (FasL) to determine whether there were differentiatio...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(99)00101-0

    authors: Bremner TA,Chatterjee D,Han Z,Tsan MF,Wyche JH

    更新日期:1999-10-01 00:00:00

  • Therapy-related myelodysplastic syndrome with inv(16)(p13q22) and I type CBFbeta/MYH11 after autologous transplantation: undetectable fusion transcript in pretransplant progenitor cells.

    abstract::We describe here a unique case of therapy-related myelodysplastic syndrome (t-MDS) with inv(16)(p13q22) after autologous stem cell transplantation for lymphoma. The rare and smallest I type CBFbeta/MYH11 fusion transcript with a breakpoint at nucleotide 399 of CBFbeta and at nucleotide 2134 of MYH11 was detected in th...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.08.001

    authors: Yamamoto K,Nishikawa S,Minagawa K,Yakushijin K,Okamura A,Matsui T

    更新日期:2006-03-01 00:00:00

  • Effective cytotoxicity against human leukemias and chemotherapy-resistant leukemia cell lines by N-N-dimethylsphingosine.

    abstract::We evaluated the cytotoxicity of dimethylsphingosine (DMS) against four human leukemia cell lines: two acute (HL60 and a multi-drug resistance MDR-positive derivative HL60-dox) and two blast crisis chronic myelogenous leukemias (JFP1, from a treatment refractory patient and K562), and against blasts isolated from 11 l...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(01)00129-1

    authors: Jendiroba DB,Klostergaard J,Keyhani A,Pagliaro L,Freireich EJ

    更新日期:2002-03-01 00:00:00

  • The expression and function of E3 ligase SIAH2 in acute T lymphoblastic leukemia.

    abstract:INTRODUCTION:The seven in absentia homolog 2 (SIAH2) protein plays a significant role in human cancer by regulating hypoxia-inducible factor-a (HIF-1α); however, its role in T-cell acute lymphoblastic leukemia (T-ALL) is less clear. METHODS:Immunofluorescence evaluation of SIAH2 protein expression and location were co...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2016.01.013

    authors: Chen H,Wang N,Yang G,Guo Y,Shen Y,Wang X,Zhang P,Xu Y

    更新日期:2016-03-01 00:00:00

  • Comparison of 18F FDG PET-CT AND CECT in pretreatment staging of adults with Hodgkin's lymphoma.

    abstract::We compared 2-[fluorine-18] fluoro-2-deoxy-d-glucose PET-CT and contrast-enhanced computed tomography (CECT) in 62 consecutive patients with newly diagnosed Hodgkin Lymphoma (HL), aiming to provide evidences that may spare CECT from the staging procedures of HL patients. Among a total of 1448 nodal sites examined, dis...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2018.11.018

    authors: Panebianco M,Bagni O,Cenfra N,Mecarocci S,Ortu La Barbera E,Filippi L,Codacci-Pisanelli G,Biondi T,Laghi A,Cimino G

    更新日期:2019-01-01 00:00:00

  • Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.

    abstract::Allogeneic stem cell transplantation is considered to be a curative treatment modality in patients with chronic myelogenous leukemia. However patients are at risk for relapse years after transplantation. Currently we present two patients who relapsed 16 and 24 years after allogeneic bone marrow transplantation, respec...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.03.010

    authors: Sekhri A,Liu D,Rasul M,Ahmed N,Ahmed T,Seiter K

    更新日期:2009-09-01 00:00:00

  • Interleukin 4 production by peripheral blood lymphocytes in patients with classical Hodgkin lymphoma.

    abstract::Although the production of interleukin (IL) 2 and interferon (IFN) gamma by peripheral blood lymphocytes in patients with Hodgkin lymphoma (HL) is well documented, the synthesis of IL4 has not been investigated before. The present study examines the production of IL4 by 2-day phytohaemaglutinin (PHA)-stimulated periph...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(03)00216-9

    authors: Mainou-Fowler T,Proctor SJ,Taylor PR

    更新日期:2004-02-01 00:00:00

  • A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.

    abstract::Older patients with acute myelogenous leukemia (AML) have overexpression of P-glycoprotein (Pgp+), and this has been shown to correlate quantitatively with therapeutic outcome. Since Pgp-mediated efflux of cytotoxic drugs can be inhibited by the cyclosporine analogue, PSC 833, we investigated the use of this agent wit...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0145-2126(00)00024-2

    authors: Chauncey TR,Rankin C,Anderson JE,Chen I,Kopecky KJ,Godwin JE,Kalaycio ME,Moore DF,Shurafa MS,Petersdorf SH,Kraut EH,Leith CP,Head DR,Luthardt FW,Willman CL,Appelbaum FR

    更新日期:2000-07-01 00:00:00

  • A leukemic plasmacytoid dendritic cell line, PMDC05, with the ability to secrete IFN-alpha by stimulation via Toll-like receptors and present antigens to naïve T cells.

    abstract::We established a plasmacytoid dendritic cell (pDC) line (PMDC05) from leukemia cells of pDC leukemia. PMDC05 cells were positive for CD4, CD56, CD33, HLA-DR, CD123 (IL-3Ralpha) and CD86 in the absence of lineage markers. mRNA of TLR1, TLR2, TLR4, TLR7 and TLR9 was clearly expressed and among these TLRs, TLR7 was promi...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.03.047

    authors: Narita M,Watanabe N,Yamahira A,Hashimoto S,Tochiki N,Saitoh A,Kaji M,Nakamura T,Furukawa T,Toba K,Fuse I,Aizawa Y,Takahashi M

    更新日期:2009-09-01 00:00:00

  • Expression of the testis-specific gene, TSGA10, in Iranian patients with acute lymphoblastic leukemia (ALL).

    abstract::Testis-specific gene antigen (TSGA10) is expressed in fetus, testis and frequently in human solid cancers and acute leukemias, making it a candidate for immunotherapy and for detection of minimal residual disease (MRD). This gene is considered as a member of cancer-testis (CT) genes. We previously demonstrated TSGA10 ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.11.012

    authors: Mobasheri MB,Modarressi MH,Shabani M,Asgarian H,Sharifian RA,Vossough P,Shokri F

    更新日期:2006-07-01 00:00:00

  • CD14 mediated endogenous TNF-alpha release in HL60 AML cells: a potential model for CD14 mediated endogenous cytokine release in the treatment of AML.

    abstract::In previous studies, HL60 AML cells treated with tumor necrosis factor-alpha (TNF), interferon-gamma (IFN), and lipopolysaccharides (LPS) displayed decreased growth and viability, enhanced monocytic pathway differentiation and endogenous TNF release. Endogenous TNF release by LPS/TNF/IFN treated HL60 cells was postula...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(94)90004-3

    authors: Treon SP,Anand B,Ulevitch R,Broitman SA

    更新日期:1994-01-01 00:00:00

  • Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia.

    abstract::We wondered whether there was any association between the extent of increased angiogenesis and IgV(H) gene mutational status, expression of CD38 and ZAP-70 in early B-cell chronic lymphocytic leukemia (CLL) patients. Circulating levels of vascular endothelial growth factor (VEGF) correlated positively with ZAP-70-expr...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2007.03.009

    authors: Molica S,Cutrona G,Vitelli G,Mirabelli R,Molica M,Digiesi G,Ribatti D,Ferrarini M,Vacca A

    更新日期:2007-11-01 00:00:00

  • Partial restoration of all trans retinoic acid (ATRA) sensitivity by compactin in ATRA-resistant leukemic cells (ATRA-R HL-60).

    abstract::The resistance to all trans retinoic acid (ATRA) differentiating treatment is a consequence, in most of the cases, of either increased catabolism or down regulation of ATRA uptake. Recently, we have shown that ATRA efficiency to differentiate HL-60 cells was enhanced about 30 times after its incorporation into Low Den...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(00)00019-9

    authors: Gueddari N,Madoulet C,Lefebvre P,Berthou L,Chomienne C,Jardillier JC

    更新日期:2000-06-01 00:00:00

  • Preclinical studies of a panel of 12 monoclonal antibodies in view of bone marrow purging in acute lymphoblastic leukemia.

    abstract::We analysed the optimal conditions for autologous bone marrow purging using complement binding monoclonal antibodies (mAbs). Twelve mAbs belonging to four clusters (CD9, CD10, CD19, CD24), alone or combined were evaluated by using direct cytotoxicity and clonogenic assays. We observed the following data: (1) optimal c...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(87)90117-2

    authors: Racadot E,Herve P,Lamy B,Peters A

    更新日期:1987-01-01 00:00:00

  • Detection of fos oncogene products by monoclonal antibody FO-120 in lymphoproliferative disorders.

    abstract::We investigated the expression of fos oncogene proteins in lymphoproliferative disorders, using a monoclonal antibody (FO-120) that was prepared against a synthetic oligopeptide of fos protein (amino acid sequence from 127 to 152). Although peripheral blood leukocytes were rarely positive for FO-120, they were transie...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(89)90010-6

    authors: Kanaitsuka T,Namba Y,Zu YL,Ishii K,Ashihara T,Hanaoka M,Suchi T

    更新日期:1989-01-01 00:00:00

  • Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome.

    abstract::Telomere dysfunction might generate genomic instability leading to the progression of myelodysplastic syndromes (MDS) into acute myeloid leukemia (AML). We investigated telomere length (TL), telomerase activity (TA) and hTERT, c-myc, mad1, and p53 expression in the bone marrow of patients with MDS (n=109), AML (n=47) ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2013.07.022

    authors: Poloni A,Serrani F,Berardinelli E,Maurizi G,Mariani M,Costantini B,Trappolini S,Mancini S,Olivieri A,Leoni P

    更新日期:2013-11-01 00:00:00

  • Cancer chemotherapy reduces plasma total antioxidant capacity in children with malignancies.

    abstract::The sum of endogenous and food-derived antioxidants provides an estimate of the total antioxidant capacity (TAC) of the extracellular fluids, while corrected TAC (cTAC) is an estimation of the exogenously provided antioxidants. Similar values for TAC and cTAC were observed between cancer free children and children wit...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2004.04.017

    authors: Papageorgiou M,Stiakaki E,Dimitriou H,Malliaraki N,Notas G,Castanas E,Kalmanti M

    更新日期:2005-01-01 00:00:00

  • Ph-negative acute lymphocytic leukemia occurring after interferon therapy for Ph-positive chronic myelocytic leukemia.

    abstract::We report a unique case of chronic myelocytic leukemia (CML) with the Philadelphia (Ph) chromosome. The patient obtained cytogenetic complete remission (CR) after treatment with interferon (IFN). When he transformed to acute lymphocytic leukemia (ALL), cytogenetic analysis showed that the karyotype was normal and fluo...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(02)00175-3

    authors: Zhang X,Ji L,Liu S,Wang J

    更新日期:2003-04-01 00:00:00

  • Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia.

    abstract::Ectopic expression of LMO2 occurs in approximately 45% of T-lineage acute lymphoblastic leukemias (T-ALL), sometimes in association with chromosomal translocations. Recently, a lymphoproliferative disorder developed in two participants in a gene therapy trial due to LMO2 activation via integration of the retroviral ve...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2004.05.013

    authors: Hammond SM,Crable SC,Anderson KP

    更新日期:2005-01-01 00:00:00